FDA Advises Medication Error Risk Assessment Early In Development

Manufacturers should assess consumers’ use of products in “real world” settings early in the development process to minimize medication errors, FDA suggests in a draft guidance on safety considerations for product and container design.

Assessments early in development can help identify and reduce potential medication errors and avoid costly post-approval redesigns, the agency says in the draft